Genmab | GEN - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Almirall EUR 214.79M 0 2025-12
Amarin USD 20.81M 13K 2025-12
Amgen USD 541M 0 2026-09
argenx SE USD 62.54M 2.74M 2026-06
AstraZeneca USD 1.55B 28K 2026-09
Bayer EUR 982.42M 0 2026-09
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Demant DKK 208.86M 2.04M 2026-06
Exelixis USD 244.68M 4.21M 2026-09
Fresenius Medical Care EUR 266.11M 3.98M 2026-06
Genmab DKK 61.44M 181K 2026-06
GlaxoSmithKline GBP 2.02B 2.05B 2026-09
GN Store Nord DKK 145.61M 0 2026-06
GRIFOLS EUR 680.58M 0 2026-09
Hikma Pharmaceutical USD 221.89M 181.89M 2025-12
Insmed USD 218.28M 1.76M 2026-06
Lakefront Biotherapeutics EUR 65.66M 242K 2026-06
Lonza CHF 68.64M 0 2025-12
Merck EUR 434.78M 0 2026-06
Novartis USD 1.89B 12.09M 2026-09
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Roche Holding CHF 796.77M 1.15M 2026-06
Sanofi EUR 1.2B 0 2026-09
UCB EUR 190.36M 365.15K 2025-12